A detailed history of Freestone Capital Holdings, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Freestone Capital Holdings, LLC holds 20,000 shares of AVXL stock, worth $217,399. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 13,800 44.93%
Holding current value
$217,399
Previous $58,000 94.83%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.11 - $7.04 $25,482 - $43,648
6,200 Added 44.93%
20,000 $113,000
Q1 2024

Nov 22, 2024

SELL
$4.55 - $6.75 $28,210 - $41,850
-6,200 Reduced 31.0%
13,800 $70,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $24,890 - $35,606
3,800 Added 38.0%
13,800 $90,000
Q2 2023

Aug 09, 2023

BUY
$7.66 - $9.5 $76,600 - $95,000
10,000 New
10,000 $81,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $847M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Freestone Capital Holdings, LLC Portfolio

Follow Freestone Capital Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Capital Holdings, LLC with notifications on news.